Joint ASTCT + EBMT Basic and Translational Scientific Meeting - Joint American Society of Transplantation and Cellular Therapy + European Society for Blood and Marrow Transplantation Basic and Translational Scientific Meeting

An RNA- and lipid nanoparticle–based platform derived from non-LTR transposons enables stable in vivo CAR T-cell engineering.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

New findings suggest that differences in immune reconstitution kinetics may drive variations in graft-versus-host disease incidence, infection risk, and overall survival.